Azacitidine in AML: a treatment option?

Blood. 2015 Jul 16;126(3):283-4. doi: 10.1182/blood-2015-06-648071.

Abstract

In this issue of Blood, Dombret et al report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).

Publication types

  • Comment

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Azacitidine / therapeutic use*
  • Blast Crisis / drug therapy*
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / mortality*
  • Male

Substances

  • Antimetabolites, Antineoplastic
  • Azacitidine